Scholarlink

Purpose <p>To assess the use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in routine clinical practice in Spain, as well as the perceptions from oncologists.</p> Methods <p>A survey was developed by nine oncologists, experts in breast cancer, practising in Spain. Survey responses were collected between July 2022 and April 2023.</p> Results <p>Fifty-one survey responses were obtained. Most oncologists used CDK4/6 inhibitors in the first line. The first-line endocrine therapy most frequently used was an aromatase inhibitor (endocrine-sensitive disease) and fulvestrant (endocrine-resistant disease). CDK4/6 inhibitors were used for primary or secondary resistance, or visceral disease without visceral crisis. A lower-than-standard starting dose was considered (57% of respondents) for specific profiles. Strategies to manage toxicity included switching to another CDK4/6 inhibitor or delaying the next dose. CDK4/6 inhibitors were mostly considered to improve quality of life.</p> Conclusions <p>Use of CDK4/6 inhibitors in Spain follows current recommendations and aligns with the evidence.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

CDK4/6 inhibitors for metastatic breast cancer in routine clinical practice in Spain: survey of patterns of use and oncologists’ perceptions

  • 期刊论文

  • 发表日期：

    2025年3月27日

查看全文
  • F. Moreno,
  • V. Iranzo,
  • I. Álvarez,
  • A. Antón,
  • J. I. Chacón,
  • J. Gavilá,
  • M. Martín,
  • P. Sánchez Rovira,
  • P. Gratal,
  • M. J. Fernández González,
  • R. López

摘要

Purpose

To assess the use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in routine clinical practice in Spain, as well as the perceptions from oncologists.

Methods

A survey was developed by nine oncologists, experts in breast cancer, practising in Spain. Survey responses were collected between July 2022 and April 2023.

Results

Fifty-one survey responses were obtained. Most oncologists used CDK4/6 inhibitors in the first line. The first-line endocrine therapy most frequently used was an aromatase inhibitor (endocrine-sensitive disease) and fulvestrant (endocrine-resistant disease). CDK4/6 inhibitors were used for primary or secondary resistance, or visceral disease without visceral crisis. A lower-than-standard starting dose was considered (57% of respondents) for specific profiles. Strategies to manage toxicity included switching to another CDK4/6 inhibitor or delaying the next dose. CDK4/6 inhibitors were mostly considered to improve quality of life.

Conclusions

Use of CDK4/6 inhibitors in Spain follows current recommendations and aligns with the evidence.